#USA #Boston #TTX-MC138 #microRNA-10b #TransCode Therapeutics

TransCode Therapeutics Publishes Groundbreaking Results on TTX-MC138

TransCode Therapeutics, Inc., a clinical-stage firm dedicated to innovating immunotherapy and RNA-based treatments for serious cancers, has made significant strides recently. On August 31, 2026, the company announced the publication of an article in the renowned journal Cancers, highlighting crucial findings from their research involving the therapeutic candidate TTX-MC138.

Overview of the Study

The study titled "Targeting miR-10b in Breast Cancer Bone Colonization Model Using Image-Guided Nucleic Acid-Based Therapeutics" presents evidence of TTX-MC138's ability to improve survival in models of breast cancer that exhibit bone metastasis. This promising data underscores the unique approach of targeting microRNA-10b, a gene that has emerged as a critical player in cancer metastasis.

Conducted by a team led by Dr. Anna Moore, a co-founder of TransCode and well-regarded authority in molecular imaging, the research used preclinical models to evaluate the efficacy of TTX-MC138. The results demonstrated that the treatment not only significantly increased survival rates but also showed favorable tolerability, with no observable systemic toxicity disrupted during the study.

Key Findings

The findings of the study reveal remarkable aspects of TTX-MC138:

• - Absorption in Metastatic Sites: TTX-MC138 was successfully localized at metastatic sites in the bones of mouse models following systemic administration, confirming its targeted delivery capabilities.
• - MicroRNA Expression Changes: The study reported a significant reduction in the expression of miR-10b, known for its role in cancer progression, while boosting the expression of HOXD10, a tumor suppressor.
• - Survival Benefits: Mice that received treatment saw a notable enhancement in survival compared to control groups, reinforcing the drug's potential impact.
• - Well-Tolerated Treatment: The repeated dosing of TTX-MC138 showcased commendable tolerability, with no indications of adverse systemic effects.

In conclusion, the study champions the use of TTX-MC138 as a potentially transformative therapeutic option for patients suffering from breast cancer bone metastases. The research emphasizes the importance of innovative anti-miR therapies in tackling metastatic cancer, an area traditionally challenging to address in oncology.

Implications for Future Research

This publication significantly supports TransCode's ongoing clinical development initiatives. Focused currently on metastatic cancers, especially those with molecular residuals in colorectal cancer, the company foresees the applicability of miR-10b inhibition in treating varying metastatic diseases.

As such, the publication serves as a stepping stone toward expanding the clinical landscape of RNA-targeted therapeutics. It opens doors for exploring additional cancer types, thereby addressing the unmet medical needs of patients. Zdravka Medarova, Ph.D., Chief Scientific Officer at TransCode, remarked that the findings confirm the substantial influence of miR-10b on survival in difficult-to-treat metastatic conditions.

About TransCode Therapeutics

TransCode Therapeutics is at the forefront of developing innovative solutions for advanced and high-risk cancers through RNA-targeted therapies. Their pioneering candidate, TTX-MC138, aims to tackle tumors that exhibit elevated levels of microRNA-10b, marking a significant step in the treatment of metastatic cancer. The results from the current study serve as a testament to their commitment to pioneering effective cancer therapies.

For ongoing updates and more information, visit TransCode Therapeutics.